RT Journal Article
SR Electronic
A1 Rizzo, Toni
T1 Long-Term Dabigatran Extension Study for Stroke Prevention in Treatment for Atrial Fibrillation
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 18
SP 25
OP 26
DO 10.1177/155989771218016
UL http://mdc.sagepub.com/content/12/18/25.abstract
AB Previously, the Randomized Evaluation of Long-Term Anticoagulation Therapy [RE-LY] trial evaluated two doses of dabigatran (110 and 150 mg BID; open dabigatran but blinded dose) versus warfarin (open-label) in patients with nonvalvular atrial fibrillation and at least 1 risk factor for stroke [Flaker et al. J Am Coll Cardiol 2012]. The goal of the RELY-ABLE extension study [NCT00808067] was to describe the long-term efficacy and safety of ongoing dabigatran therapy after the RE-LY trial.